



-

BioLight Life Sciences
("the company")

March 1, 2022

To:

Israel Security Authority
www.isa.goc.il

TASE- Tel Aviv Stock Exchange
www.tase.co.il

Subject-

Exercise of the Company's investment option in AEYE Health inc. (portfolio company)

Following the Company's announcement dated March 2, 2021, regarding investment in AEYE Health Inc. ("AEYE") in accordance with an investment agreement signed between the Company and other investors and AEYE (the "Investment Agreement"), and following the Company's announcement dated February 15, 2022, indicating positive test results in a pivotal clinical trial of AEYE's product for the diagnosis of diabetic retinopathy, the Company is honored to update that on February 28, 2022, the Company exercised its option to purchase additional B shares of AEYE, in accordance with the terms of the Investment Agreement, in the amount of \$1 million USD. The exercise of the option by the Company was also exercised by other investors who invested in AEYE alongside the Company in the framework of the investment agreement of 2021 in the amount of approximately \$ 1.1 million USD.

Following the exercise of the options by the Company and the additional investors as aforesaid, the Company holds approximately 8.2% of the issued share capital of AEYE.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye diseases and their treatment. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies. The Ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.

About AEYE Health

AEYE Health is a digital health company that provides fully autonomous, AI-based diagnostic

screening solutions for retinal imaging with best-in-class clinical results for vision threatening diseases such as diabetic retinopathy, retinal degeneration (AMD), glaucoma and other retinal diseases. AEYE aims to make diagnostic screening practical, accurate and accessible.